Suppliers / Jiangsu Jiaerke Pharmaceuticals Group

Jiangsu Jiaerke Pharmaceuticals Group

China Updated 9 July 2026

Jiangsu Jiaerke Pharmaceuticals Group is a contract manufacturer based in China. It holds 6 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 12 September 2025 as VAI.

6
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 12 September 2025 VAI US FDA
  • 26 July 2018 VAI US FDA
  • 12 June 2014 NAI US FDA
  • 28 April 2011 VAI US FDA
  • 17 September 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3001599766

What they file, and where

Molecule Regulators Docs
Prasterone US FDA 4
Progesterone SFDA (Saudi Arabia), US FDA 4

Also appears on these molecule pages

Eplerenone contract manufacturing Hydrocortisone contract manufacturing Prednisolone contract manufacturing Prednisone contract manufacturing Progesterone contract manufacturing Testosterone contract manufacturing

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Jiangsu Jiaerke Pharmaceuticals Group comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 September 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates